MX2022013791A - Nueva composición de liberación prolongada de tofacitinib, sus derivados y sales. - Google Patents

Nueva composición de liberación prolongada de tofacitinib, sus derivados y sales.

Info

Publication number
MX2022013791A
MX2022013791A MX2022013791A MX2022013791A MX2022013791A MX 2022013791 A MX2022013791 A MX 2022013791A MX 2022013791 A MX2022013791 A MX 2022013791A MX 2022013791 A MX2022013791 A MX 2022013791A MX 2022013791 A MX2022013791 A MX 2022013791A
Authority
MX
Mexico
Prior art keywords
tofacitinib
extended release
release composition
derivatives
salts
Prior art date
Application number
MX2022013791A
Other languages
English (en)
Inventor
Anwar Daud
Chandrashekhar Mainde
Uttam Kedar
Kuldeep Gangawat
Original Assignee
Zim Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zim Laboratories Ltd filed Critical Zim Laboratories Ltd
Publication of MX2022013791A publication Critical patent/MX2022013791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona a una composición sólida de Tofacitinib y sal del mismo, y proceso de fabricación de la misma. La presente invención se relaciona a una composición de liberación extendida no osmótica que comprende Tofacitinib o una sal del mismo, una mezcla de óxidos de polietileno junto con uno o más excipientes farmacéuticamente aceptables. La composición de liberación extendida no osmótica de Tofacitinib o sal del mismo se utiliza en el tratamiento de Artritis Reumatoide, Artritis Psoriática y Colitis Ulcerativa.
MX2022013791A 2020-05-18 2021-05-17 Nueva composición de liberación prolongada de tofacitinib, sus derivados y sales. MX2022013791A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021020825 2020-05-18
PCT/IB2021/054195 WO2021234530A1 (en) 2020-05-18 2021-05-17 Novel extended release composition of tofacitinib, its derivatives and salts

Publications (1)

Publication Number Publication Date
MX2022013791A true MX2022013791A (es) 2023-02-15

Family

ID=78708184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013791A MX2022013791A (es) 2020-05-18 2021-05-17 Nueva composición de liberación prolongada de tofacitinib, sus derivados y sales.

Country Status (6)

Country Link
US (1) US20230172934A1 (es)
EP (1) EP4153138A4 (es)
AU (1) AU2021274145A1 (es)
BR (1) BR112022022284A2 (es)
MX (1) MX2022013791A (es)
WO (1) WO2021234530A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887408B (zh) * 2022-11-29 2024-05-24 江苏慧聚药业股份有限公司 包含托法替布的药物组合物和药物制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013144975A (ru) * 2011-04-08 2015-05-20 Пфайзер Инк. Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
JP6041823B2 (ja) * 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
EP3810096A1 (en) * 2018-05-24 2021-04-28 Synthon B.V. Controlled release tofacitinib compositions

Also Published As

Publication number Publication date
US20230172934A1 (en) 2023-06-08
EP4153138A1 (en) 2023-03-29
AU2021274145A1 (en) 2023-01-05
EP4153138A4 (en) 2024-06-05
WO2021234530A1 (en) 2021-11-25
BR112022022284A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MX2020013373A (es) Compuestos de naftiridinona utiles como activadores de celulas t.
MD4625C1 (ro) Derivaţi de 5-fenoxi-3H-pirimidin-4-onă şi utilizarea acestora ca inhibitori ai transcriptazei inverse a HIV
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
CR20210608A (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
MX2009006285A (es) Inhibidores de transcriptasa inversa no nucleosidicos.
IS7892A (is) Tetrahýdró-4H-pýridó[1,2-A]pýrimidín og tengd efnasambönd sem nýtast sem HIV integrasa hindrar
MX2022007369A (es) Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
MX2021007833A (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.
MY163979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
MX2022013791A (es) Nueva composición de liberación prolongada de tofacitinib, sus derivados y sales.
PH12020551638A1 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
EA201170537A1 (ru) Ингибиторы вич-интегразы
MX2022009043A (es) Compuestos de sulfonimidamida como moduladores de nlrp3.
CL2023001367A1 (es) Inhibidores de btk
MX2023005086A (es) Compuestos de pirimidina, composiciones y aplicaciones medicas de esta.